What is a regulatory gap assessment?
A regulatory gap assessment is a structured review of your current documentation, quality systems, and evidence against the requirements of a target regulation. For EU MDR, this typically includes technical documentation, GSPR compliance, clinical evidence, risk management, labeling, and post-market processes. The goal is to identify deficiencies, rank them by severity, and create a practical remediation roadmap before submission or audit.
What are the 4 steps in a gap analysis?
The four core steps are defining the target requirements, reviewing your current state, identifying and documenting the gaps, and building a remediation plan. In an EU MDR context, that means mapping applicable regulatory requirements, assessing existing files and systems, recording each deficiency with supporting references, and prioritizing corrective actions by risk, effort, and submission impact.
What does an EU MDR gap assessment include?
An EU MDR gap assessment typically reviews Annex II and III technical documentation, GSPR conformity, clinical evaluation, PMCF, PMS, risk management, labeling, and QMS alignment. A strong assessment also checks traceability across documents, identifies missing or weak evidence, and links each finding to the relevant EU MDR article, annex, or guidance so remediation can be executed efficiently.
How is remediation different from a gap assessment?
A gap assessment identifies what is missing, incomplete, inconsistent, or noncompliant. Remediation is the follow-through work required to fix those issues. That may include rewriting technical documentation sections, updating CERs, strengthening risk files, revising labeling, improving PMS procedures, or reorganizing evidence for Notified Body review. Effective remediation turns findings into submission-ready outputs.
When should a manufacturer start EU MDR remediation?
Manufacturers should begin remediation as soon as meaningful gaps are identified, ideally well before engaging a Notified Body or committing to a submission timeline. Starting early helps avoid rushed documentation updates, duplicated work, and preventable review delays. It is especially important for companies transitioning from MDD or reactivating a previously delayed CE marking program.
Can you help with legacy MDD to EU MDR transition gaps?
Yes. Transitioning from MDD to EU MDR often reveals major gaps in clinical evidence, PMS, PMCF, GSPR mapping, and technical documentation depth. Elexes helps manufacturers benchmark legacy files against current EU MDR expectations, identify what can be retained, and prioritize the updates needed to create a defensible, Notified Body-ready compliance package.
How long does an EU MDR gap assessment take?
The timeline depends on device complexity, classification, documentation maturity, and the scope of review. A focused assessment of a limited file set may move faster, while a full review covering technical documentation, CER, PMS, labeling, and QMS alignment takes longer. The most effective engagements define scope early and deliver findings in prioritized phases so remediation can begin immediately.
What deliverables should I expect from this service?
You should expect a structured findings report, regulatory references for each gap, severity rankings, and a prioritized remediation plan. Many manufacturers also need annotated document feedback, traceability observations, and practical recommendations on sequencing corrective actions. The best deliverables do not just list problems; they provide a clear path to stronger EU MDR readiness and submission defensibility.